Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
43pct
1d open
vs 9,698 other HR bills in the 117th — cohort avg 63d
Plain Prescription Prices Act This bill requires the Centers for Medicare & Medicaid Services to issue a rule requiring direct-to-consumer television advertisements for prescription drugs that are covered by Medicare or Medicaid to include a textual statement of the drug's list price.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (2)
2022 · fourth_quarter · Pharmacy
Issues related to implementation of the drug pricing provisions of the Inflation Reduction Act of 2022 H.R.7529 - Plain Prescription Prices Act - in support
Client expense: Not reported · Firm income: $10,000
Referred to the Subcommittee on Health.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: HOUSE OF REPRESENTATIVES, SENATE
S. 4953, Protecting Drug Innovation Act. H.R.7529, Plain Prescription Prices Act. No bill number. Discussed access to COVID-19 vaccines, tests, and treatments. No bill number. Discussed allowing Medicare Part D enrollees a one-time plan switch. No bill number. Discussed new payment and delivery models to lower drug costs and promote access to innovative drug therapies. H.R. 8239/S. 4661 Agriculture, Rural Development & FDA Appropriations, FY 2023. No bill number. Discussed drug price transparency.
Client expense: $4,180,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2022 · second_quarter · Pharmacy
H.R.7473 Generic Substitution Noninterference Act - in support H.R.7474 - Pharmaceutical Research Transparency Act of 2022 - in support H.R.7529 - Plain Prescription Prices Act - in support H.R.7828 - PRICED Act - in support H.R.8289 - Banning Misleading Drug Ads Act of 2022 - in support H.R.7472 - Discounted Drugs for Clinical Trials Act - in support
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE